GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hypha Labs Inc (OTCPK:FUNI) » Definitions » Cash, Cash Equivalents, Marketable Securities

FUNI (Hypha Labs) Cash, Cash Equivalents, Marketable Securities : $0.04 Mil (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hypha Labs Cash, Cash Equivalents, Marketable Securities?

Hypha Labs's quarterly cash, cash equivalents, marketable securities declined from Jun. 2024 ($0.51 Mil) to Sep. 2024 ($0.09 Mil) but then stayed the same from Sep. 2024 ($0.09 Mil) to Dec. 2024 ($0.04 Mil).

Hypha Labs's annual cash, cash equivalents, marketable securities increased from Sep. 2022 ($0.06 Mil) to Sep. 2023 ($0.27 Mil) but then declined from Sep. 2023 ($0.27 Mil) to Sep. 2024 ($0.09 Mil).


Hypha Labs Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Hypha Labs's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypha Labs Cash, Cash Equivalents, Marketable Securities Chart

Hypha Labs Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.30 0.06 0.27 0.09

Hypha Labs Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 1.06 0.51 0.09 0.04

Hypha Labs Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Hypha Labs  (OTCPK:FUNI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Hypha Labs Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Hypha Labs's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Hypha Labs Business Description

Industry
Traded in Other Exchanges
N/A
Address
5940 S. Rainbow Boulevard, Las Vegas, NV, USA, 89118
Hypha Labs Inc is engaged in the research, development and commercialization of a bioreactor, the Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of nutritionally beneficial mushrooms for human consumption.
Executives
A Stone Douglass director 10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank director 19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda officer: Chief Executive Officer 111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann director 1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben director 430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser director 4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer director 287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco director 611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson officer: Chief Financial Officer 3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner director 28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc 10 percent owner 16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin director, officer: President C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee 10 percent owner 3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen director, 10 percent owner, officer: CFO 8908 SPLITARROW DRIVE, AUSTIN TX 78717